Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes with chimeric antigen receptor-t cell therapy in relapsed/refractory b-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHafiz Muhammad Asif Javed

Discussion

Loading...

Member takes

Overview

Meta-analysis shows CAR-T cell therapy improves remission rates and overall survival in relapsed B-ALL, indicating potential for durable treatment options.

Key Points

  • This research analyzes the effectiveness of CAR-T cell therapy in patients with relapsed/refractory B-ALL.
  • Systematic review following PRISMA guidelines
  • Analysis of eight studies reporting CAR-T outcomes
  • Meta-analysis using a random-effects model to pool results
  • Pooled overall response rate was 78%
  • Complete remission rate was 66%
  • Overall survival at 12 months was 69%

Cite This Study

Hafiz Muhammad Asif Javed (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1f6https://doi.org/10.1182/blood-2025-6875
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis2025
  2. 2CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues2025 · 4 citations
  3. 3Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  4. 4Chimeric Antigen Receptor T-cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Efficacy, Safety, and Future Directions2025 · 1 citations
  5. 5Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study2025